Researchers at Duke University found that blocking a key enzyme not only kills multiple myeloma (MM) cancer cells but also boosts the effectiveness of existing therapies. MM is an incurable blood cancer, and drug resistance is an increasing problem. The study, published in Blood, focused on ferroptosis, a natural form of cell death triggered by […]
The Iron Kill-Switch: How Iron Forces Cancer Cells to Self-Destruct Read More »
A new study from University of Chicago, published in Cell Reports Medicine, suggests that zeaxanthin, a plant carotenoid known for eye health, may also boost the immune system’s ability to fight cancer. The compound enhances CD8+ T cells, the body’s tumor-killing immune cells, by stabilizing their T-cell receptor (TCR) complex, leading to stronger activation and
Common Nutritional Aid Shows Promise in Strengthening Cancer Therapy Read More »
Cancer patients are at high risk for severe COVID-19, making extra vaccine doses important. This study assessed their effectiveness using real-world data. In the monovalent booster period (up to August 2022), an additional dose reduced hospitalizations (29.2% effectiveness), with rates of 30.5 per 1,000 person-years in boosted patients compared to 41.9 in those with only
In Phase II study for extensive-stage small-cell lung cancer (ES-SCLC), the novel intercalated administration of the anti-PD-L1 inhibitor avelumab with platinum-etoposide chemotherapy (avelumab started after cycle 2) did not meet the primary endpoint of a 25% one-year progression-free survival (PFS), achieving 12.7% (median PFS: 5.8 months). Despite this, the treatment demonstrated high anti-tumor activity with an Objective Response
Intercalated Avelumab with Chemotherapy in ES-SCLC: A Phase II Efficacy and Safety Study Read More »
Gastroesophageal cancers, though relatively uncommon in the U.S., cause significant morbidity and mortality worldwide. For early-stage gastric and gastroesophageal junction (GEJ) adenocarcinoma, the primary goal is cure, achieved through multimodality treatment. Landmark trials demonstrated the benefits of perioperative chemotherapy, such as the MAGIC trial’s pECF regimen, and neoadjuvant chemoradiotherapy, like the CROSS trial’s nCROSS regimen.
Cancer remains the second leading cause of death in the U.S., with the COVID-19 pandemic exacerbating delays in diagnosis and potentially worsening disparities and mortality. In 2025, an estimated 2,041,910 new invasive cancer cases and 618,120 deaths are expected, with roughly one in three men and women likely to be diagnosed in their lifetime. Lung
Smoking Still the Top Killer: A Look at US Cancer Cases and Deaths in 2025 Read More »
The human body, composed of approximately 37 trillion cells, lacks a clear understanding of how these cells coordinate within tissues. To address this, a comprehensive pan-tissue single-cell transcriptomic atlas of over 2.29 million cells from 35 healthy human tissues was assembled. Using a new computational framework, CoVarNet, researchers identified 12 recurring, cross-tissue Cellular Modules (CMs),
Cellular Modules: Coordination Units, Tissue Diversity, and Cancer Reprogramming Read More »
Immune checkpoint inhibitors (ICIs) help only about 25–30% of patients with advanced non–small cell lung cancer (NSCLC) lacking EGFR or ALK alterations. Traditional biomarkers such as PD-L1 expression and tumor mutational burden (TMB) are imperfect, necessitating better predictors. Recent advances in artificial intelligence (AI) now allow analysis of digital pathology images to identify immune features
AI-Powered Pathology Assessment Predicts Immunotherapy Success in Advanced Lung Cancer Read More »
The COAST trial, a randomized phase 2 study, evaluated whether adding novel immunotherapies to durvalumab could improve outcomes for patients with unresectable stage III non–small cell lung cancer (NSCLC) who had completed chemoradiotherapy without progression. Patients received durvalumab alone, durvalumab plus oleclumab (anti-CD73), or durvalumab plus monalizumab (anti-NKG2A). Updated results showed enhanced activity with both
Large B-cell lymphoma (LBCL) is the most common aggressive non-Hodgkin lymphoma, with about 60% of patients cured by first-line therapy. Relapsed or refractory (R/R) patients have poor outcomes, with median survival around 6.3 months. Autologous CD19 CAR T-cell therapies help some patients but are limited by manufacturing delays, disease aggressiveness, and access barriers. Cemacabtagene ansegedleucel
Allogeneic CD19 CAR T Therapy Shows Safety & Efficacy in R/R Large B-Cell Lymphoma Read More »